Tetramers used in the study
| Virus/protein . | Amino acids . | Sequence . | Restricting element . | References . | HIV-seropositive donors . | Healthy donors . | ||
|---|---|---|---|---|---|---|---|---|
| Subjects with recognition of tetramer . | Frequency of CD8 T cells, range (%) . | Subjects with recognition of tetramer . | Frequency in CD8 T cells, range (%) . | |||||
| HIV/gag | 77-85 | SLYNTVATL | A0201 | 17, 23, 24 | 2/5 | 0.21-0.22 | 0 | |
| HIV/RT | 309-317 | ILKEPVHGV | A0201 | 17, 24, 25 | 2/4 | 0.36-0.95 | 0 | |
| HIV/env | 593-600 | YLKDQQLL | B8 | 26 | 3/7 | 0.05-0.11 | 0 | |
| CMV/pp65 | 495-503 | NLVPMVATV | A0201 | 27-29 | 4/5 | 0.18-11 | 3/8 | 0.25-4.85 |
| EBV/BMLF1 | 280-288 | GLCTLVAML | A0201 | 30, 31 | 4/5 | 0.02-0.16 | 4/8 | 0.08-0.12 |
| EBV/BZLF1 | 190-197 | RAKFKQLL | B8 | 30, 31 | 6/6 | 0.18-3.06 | 1/1 | 0.37 |
| Virus/protein . | Amino acids . | Sequence . | Restricting element . | References . | HIV-seropositive donors . | Healthy donors . | ||
|---|---|---|---|---|---|---|---|---|
| Subjects with recognition of tetramer . | Frequency of CD8 T cells, range (%) . | Subjects with recognition of tetramer . | Frequency in CD8 T cells, range (%) . | |||||
| HIV/gag | 77-85 | SLYNTVATL | A0201 | 17, 23, 24 | 2/5 | 0.21-0.22 | 0 | |
| HIV/RT | 309-317 | ILKEPVHGV | A0201 | 17, 24, 25 | 2/4 | 0.36-0.95 | 0 | |
| HIV/env | 593-600 | YLKDQQLL | B8 | 26 | 3/7 | 0.05-0.11 | 0 | |
| CMV/pp65 | 495-503 | NLVPMVATV | A0201 | 27-29 | 4/5 | 0.18-11 | 3/8 | 0.25-4.85 |
| EBV/BMLF1 | 280-288 | GLCTLVAML | A0201 | 30, 31 | 4/5 | 0.02-0.16 | 4/8 | 0.08-0.12 |
| EBV/BZLF1 | 190-197 | RAKFKQLL | B8 | 30, 31 | 6/6 | 0.18-3.06 | 1/1 | 0.37 |
HIV indicates human immunodeficiency virus; CMV, cytomegalovirus; and EBV, Epstein-Barr virus.